Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.

Sandborn, William J; Korzenik, Joshua; Lashner, Bret; Leighton, Jonathan A; Mahadevan, Uma; Marion, James F; Safdi, Michael; Sninsky, Charles A; Patel, Raman M; Friedenberg, Keith A; Dunnmon, Preston; Ramsey, David; Kane, Sunanda

Sandborn, William J; Korzenik, Joshua; Lashner, Bret; Leighton, Jonathan A; Mahadevan, Uma; Marion, James F; Safdi, Michael; Sninsky, Charles A; Patel, Raman M; Friedenberg, Keith A; Dunnmon, Preston; Ramsey, David; Kane, Sunanda.

Affiliation

Sandborn WJ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA. sandborn.william@mayo.edu

Gastroenterology ; 138(4): 1286-96, 1296.e1-3, 2010 Apr.

Article in En | MEDLINE | ID: mdl-20064514

Subject(s)

Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Colitis, Ulcerative/drug therapy; Mesalamine/administration & dosage; Administration, Oral; Adult; Aged; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Male; Mesalamine/adverse effects; Middle Aged

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colitis, Ulcerative / Anti-Inflammatory Agents, Non-Steroidal / Mesalamine Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Gastroenterology Year: 2010 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google